# SODIUM PHOSPHATE, MONOBASIC

URL: https://app.greenveil.ai/ingredients/ingredient_unii_3980_jih2_sw
Categories: pharma
Identifier: chebi:37585

> SODIUM PHOSPHATE, MONOBASIC. Route: INTRAMUSCULAR; Dosage form: INJECTION; Maximum daily exposure: 161 mg Assessed from 12 sources.

## Safety assessment

- Chemical concern: not yet assessed
- Rationale: Route: INTRAMUSCULAR; Dosage form: INJECTION; Maximum daily exposure: 161 mg

## Regulatory status

- US: inactive ingredient database — Route: INTRAMUSCULAR; Dosage form: INJECTION; Maximum daily exposure: 161 mg
- US: inactive ingredient database — Route: INTRAVENOUS; Dosage form: INJECTION; Maximum daily exposure: 161 mg
- US: inactive ingredient database — Route: INTRAVENOUS; Dosage form: INJECTION, POWDER, FOR SOLUTION; Potency: 13.2 mg
- US: inactive ingredient database — Route: IONTOPHORESIS; Dosage form: SYSTEM; Potency: 14.2 mg
- US: inactive ingredient database — Route: ORAL; Dosage form: SOLUTION; Potency: 25 mg/5ml
- US: inactive ingredient database — Route: ORAL; Dosage form: TABLET; Maximum daily exposure: 2 mg
- US: inactive ingredient database — Route: SUBCUTANEOUS; Dosage form: INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION; Potency: 0.22 mg
- US: inactive ingredient database — Route: SUBCUTANEOUS; Dosage form: INJECTION, SUSPENSION; Potency: 0.07 %w/v
- US: inactive ingredient database — Route: TOPICAL; Dosage form: SYSTEM; Potency: 14.2 mg
- US: marketed drug occurrence — FDA NDC lists this ingredient in 8 active drug products and 8 total products.
- US: listed in openFDA substance — openFDA substance registry classifies this ingredient as mixture.

_Assessed by Greenveil._